Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 9/20 | 0.60 |
| ▸ | FLT3 | P36888 | 4/20 | 0.60 |
| ▸ | CDK1 | P06493 | 3/20 | 0.60 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.60 |
| ▸ | CDK7 | P50613 | 3/20 | 0.60 |
| ▸ | CCNH | P51946 | 3/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.60 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.60 |
| ▸ | JAK2 | O60674 | 4/20 | 0.58 |
| ▸ | JAK3 | P52333 | 3/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | PLK4 | O00444 | 2/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | CSF1R | P07333 | 1/20 | 0.55 |
| ▸ | ROS1 | P08922 | 1/20 | 0.55 |
| ▸ | KIT | P10721 | 1/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7467387 | 0.87 | CDK2 (0.64) | CDK2FLT3CDK1CCNB1CDK7 | |
| SCHEMBL4463575 | 0.85 | PLK4 (0.69) | CDK2CDK1CCNE1JAK2JAK3 | |
| SCHEMBL30306480 | 0.85 | EGFR (0.60) | CDK2FLT3CCNE1JAK2JAK3 | |
| SCHEMBL3120382 | 0.80 | CDK2 (0.68) | CDK2CDK1CCNB1CDK7CCNH | |
| SCHEMBL5104441 | 0.78 | GAA (0.55) | CDK2FLT3CDK1CCNB1CDK7 | |
| SCHEMBL14100244 | 0.77 | CDK2 (0.59) | CDK2FLT3CDK1CCNB1CDK7 | |
| SCHEMBL29368254 | 0.77 | MAP4K1 (0.60) | CDK2FLT3CDK1CCNB1CDK7 | |
| SCHEMBL4482243 | 0.77 | MKNK1 (0.45) | CDK2FLT3CDK1CCNB1CDK7 | |
| SCHEMBL34463169 | 0.77 | JAK2 (0.65) | CDK2FLT3CDK1CCNB1CDK7 | |
| SCHEMBL5090939 | 0.77 | FLT3 (0.60) | CDK2FLT3CDK1CCNB1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220073536-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-10259826-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20180072756-A1 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20120253039-A1 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-7582648-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080312438-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-7452879-B2 | N4-(1-tert-Butoxycarbonylazetidin-3-yl)-5-fluoro-N2-(4-morpholinophenyl)-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for IgE (\"Fc epsilon RI\") and IgG (\"Fc gamma RI\") antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis, multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20070167439-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-20050234049-A1 | Ring attached at N2 and N4 of 2,4-pyrimidinediamines; for treating rheumatoid arthritis; N4-(2,2-dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine | MIDCAP FINANCIAL TRUST | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10259826-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | SSB, TPMT, ADAR | CDK2 953/4885FLT3 3179/4885CDK1 2316/4885 |
| US-20220073536-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | SSB, TPMT, ADAR | CDK2 1030/4885FLT3 3116/4885CDK1 2435/4885 |
| US-20120253039-A1 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | SSB, TPMT, ADAR | CDK2 953/4885FLT3 3179/4885CDK1 2316/4885 |
| US-20180072756-A1 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | SSB, TPMT, ADAR | CDK2 953/4885FLT3 3179/4885CDK1 2316/4885 |
| US-20070167439-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | SSB, TYMS, TPMT | CDK2 1019/4885FLT3 730/4885CDK1 1309/4885 |
| US-20080312438-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | SSB, TYMS, TPMT | CDK2 1019/4885FLT3 730/4885CDK1 1309/4885 |
| US-20050234049-A1 | Ring attached at N2 and N4 of 2,4-pyrimidinediamines; for treating rheumatoid arthritis; N4-(2,2-dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine | SSB, HRH4, TLR7 | CDK2 174/4885FLT3 426/4885CDK1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.